Sharma, Rohita http://orcid.org/0000-0002-6361-0004
Ahmed, Sumaira
Campagnari, Judy
Huff, Wendi
Lloyd, Lelainia
Funding for this research was provided by:
Alexion, AstraZeneca Rare Disease
Article History
Accepted: 14 March 2023
First Online: 4 May 2023
Declarations
:
: All activities and analysis were funded by Alexion, AstraZeneca Rare Disease. Medical writing and editorial support, funded by Alexion, AstraZeneca Rare Disease, was provided by Catherine Hoare, PhD, Bioscript Medical, Macclesfield, UK. Alexion, AstraZeneca Rare Disease reviewed and provided feedback on the manuscript.
: Rohita Sharma and Judy Campagnari are employees of, and hold stocks in, Alexion, AstraZeneca Rare Disease. Judy Campagnari also has patents pending. Lelainia Lloyd has been the recipient of grants, honoraria, support for attending meetings and equipment, materials, drugs, medical writing, gifts or other services from Alexion, AstraZeneca Rare Disease; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from the MS Society of Canada; and is on the editorial board for the Journal of Medical Imaging and Radiation Sciences. Sumaira Ahmed and Wendi Huff have no competing interests to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to drafting and revising the article, provided their final approval of all content and agree to be accountable for all aspects of the work. Yiyi Xia (Director, STAR Ideation & Strategy at Alexion, AstraZeneca Rare Disease) contributed to the initial stages of the article and provided key information.